191 reports of this reaction
1.8% of all BUROSUMAB reports
#13 most reported adverse reaction
CONTRAINDICATED PRODUCT ADMINISTERED is the #13 most commonly reported adverse reaction for BUROSUMAB, manufactured by Kyowa Kirin, Inc.. There are 191 FDA adverse event reports linking BUROSUMAB to CONTRAINDICATED PRODUCT ADMINISTERED. This represents approximately 1.8% of all 10,519 adverse event reports for this drug.
Patients taking BUROSUMAB who experience contraindicated product administered should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONTRAINDICATED PRODUCT ADMINISTERED is a less commonly reported adverse event for BUROSUMAB, but still significant enough to appear in the safety profile.
In addition to contraindicated product administered, the following adverse reactions have been reported for BUROSUMAB:
The following drugs have also been linked to contraindicated product administered in FDA adverse event reports:
CONTRAINDICATED PRODUCT ADMINISTERED has been reported as an adverse event in 191 FDA reports for BUROSUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONTRAINDICATED PRODUCT ADMINISTERED accounts for approximately 1.8% of all adverse event reports for BUROSUMAB, making it a notable side effect.
If you experience contraindicated product administered while taking BUROSUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.